Co-Diagnostics Highlights PCR Platform Capabilities for Potential Plague Testing
Co-Diagnostics, Inc. (CODX) highlighted the capabilities of its Co-Dx PCR Pro point-of-care platform, noting that its technology could potentially be adapted for plague detection if a public health demand arises. The announcement follows reports of an October 2 death of a laboratory worker at a research facility in Irkutsk, Russia. Although the cause of death remains undetermined, the World Health Organization reported on October 10 that Russian officials found no evidence of plague or active transmission.
The company emphasized that it has not initiated development or design work on a plague-specific test or launched a new program. Instead, Co-Diagnostics points to its existing sputum sample-preparation tools developed for its tuberculosis program, along with experience responding to outbreaks of COVID-19, mpox, and Ebola, as a framework for potential response. None of the company's PCR platform instruments or tests have received clearance or authorization from the U.S. Food and Drug Administration, and they are not currently available for sale.
Shares of Co-Diagnostics dropped 28.22% to $0.7645 following the announcement. Investors appear cautious given that the company has no active plague product under development and its testing platform remains subject to regulatory reviews before commercial release.
Key points
- Co-Diagnostics stated its Co-Dx PCR Pro platform could potentially adapt to plague detection, but confirmed no development program has been started.
- The statement follows an Oct. 2 fatality at a Russian research institute, where WHO reported no plague or high-threat pathogens were identified by local authorities.
- The company plans to leverage its existing sputum preparation technology and past experience with COVID-19, mpox, and Ebola if testing needs arise.
- Co-Diagnostics' PCR platform and associated diagnostic tests are not FDA cleared or authorized and are not yet available for sale.
- Shares of Co-Diagnostics (CODX) fell 28.22% to $0.7645 on the day of the announcement.
Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org
How we writeDisclaimerQuestions and answers
Is Co-Diagnostics developing a test for plague?
No. Co-Diagnostics stated that it has not initiated design or development work on a plague-specific diagnostic test and is not announcing a new development program.
Are Co-Diagnostics PCR platform products FDA cleared?
No. The Co-Dx PCR platform and its associated tests have not been cleared or authorized by the FDA and are not currently available for sale.
Why did Co-Diagnostics stock decline?
Co-Diagnostics shares fell 28.22% to $0.7645 as the company clarified it has no active plague test under development and its platform awaits regulatory review.